Cargando…

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review

INTRODUCTION: Multiple sclerosis (MS) is considered an autoimmune disease with inflammatory and neurodegenerative underlying processes that affect the central nervous system. The available disease-modifying therapies (DMTs) approved to treat MS have only shown partial benefit in controlling the dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolb-Sobieraj, Channa, Gupta, Sahil, Weinstock-Guttman, Bianca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381916/ https://www.ncbi.nlm.nih.gov/pubmed/26000222 http://dx.doi.org/10.1007/s40120-014-0017-6

Ejemplares similares

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2022)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective
por: Jakimovski, Dejan, et al.
Publicado: (2020)

No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years
por: Gandhi, Sirin, et al.
Publicado: (2019)

COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections
por: Jakimovski, Dejan, et al.
Publicado: (2022)

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2019)

The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging
por: Guan, Yi, et al.
Publicado: (2019)

Iron deposition and inflammation in multiple sclerosis. Which one comes first?
por: Zivadinov, Robert, et al.
Publicado: (2011)

Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
por: Stasiolek, Mariusz, et al.
Publicado: (2015)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients()
por: Graziano, Elliot, et al.
Publicado: (2015)

Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis
por: Malyavantham, Kishore, et al.
Publicado: (2015)

Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis
por: Young, Nicholas, et al.
Publicado: (2023)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study
por: Schwartz, Carolyn E., et al.
Publicado: (2015)

Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI
por: Schweser, Ferdinand, et al.
Publicado: (2020)

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study
por: Rivera, Victor M, et al.
Publicado: (2013)

Cognitive Profiles of Aging in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2019)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals
por: Hagemeier, Jesper, et al.
Publicado: (2017)

Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Vitamin D and Multiple Sclerosis: A Comprehensive Review
por: Sintzel, Martina B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4u8i91375jjqm1fidi27kndhk0